FibroBiologics Files Patent Application for Methods to Treat Splenomegaly

MT Newswires Live

Nov 20, 2024

FibroBiologics (FBLG) said Tuesday it has filed a patent application covering methods to treat splenomegaly using a cell-based approach.

"This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly," said FibroBiologics Chief Executive Pete O'Heeron.

Hamid Khoja, the biotechnology company's chief scientific officer said, "unlike traditional treatments, fibroblasts may offer a potential solution aligned with the host biological processes to help regulate immune activity within the spleen, opening new possibilities for managing conditions that involve immune system overload and splenomegaly."

Price: 2.41, Change: -0.09, Percent Change: -3.75

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2484315924"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484315924\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2484315924?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 00:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484315924","market":"fut","top_or_hot":-1,"title":"FibroBiologics Files Patent Application for Methods to Treat Splenomegaly","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> (FBLG) said Tuesday it has filed a patent application covering methods to treat splenomegaly using a cell-based approach.</p><p>\"This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly,\" said FibroBiologics Chief Executive Pete O'Heeron.</p><p>Hamid Khoja, the biotechnology company's chief scientific officer said, \"unlike traditional treatments, fibroblasts may offer a potential solution aligned with the host biological processes to help regulate immune activity within the spleen, opening new possibilities for managing conditions that involve immune system overload and splenomegaly.\"</p><p>Price: 2.41, Change: -0.09, Percent Change: -3.75</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FibroBiologics Files Patent Application for Methods to Treat Splenomegaly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFibroBiologics Files Patent Application for Methods to Treat Splenomegaly\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-20 00:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/FBLG\">FibroBiologics</a> (FBLG) said Tuesday it has filed a patent application covering methods to treat splenomegaly using a cell-based approach.</p><p>\"This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly,\" said FibroBiologics Chief Executive Pete O'Heeron.</p><p>Hamid Khoja, the biotechnology company's chief scientific officer said, \"unlike traditional treatments, fibroblasts may offer a potential solution aligned with the host biological processes to help regulate immune activity within the spleen, opening new possibilities for managing conditions that involve immune system overload and splenomegaly.\"</p><p>Price: 2.41, Change: -0.09, Percent Change: -3.75</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484315924","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484315924","pubTimestamp":1732032371,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"FibroBiologics  said Tuesday it has filed a patent application covering methods to treat splenomegaly using a cell-based approach.\"This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly,\" said FibroBiologics Chief Executive Pete O'Heeron.Hamid Khoja, the biotechnology company's chief scientific officer said, \"unlike traditional treatments, fibroblasts may offer a potential solution aligned with the host biological processes to help regulate immune activity within the spleen, opening new possibilities for managing conditions that involve immune system overload and splenomegaly.\"Price: 2.41, Change: -0.09, Percent Change: -3.75","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FBLG":"FibroBiologics"},"translate_title":"FibroBiologics提交治疗脾肿大方法专利申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBLG":1},"content_text":"FibroBiologics (FBLG) said Tuesday it has filed a patent application covering methods to treat splenomegaly using a cell-based approach.\"This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly,\" said FibroBiologics Chief Executive Pete O'Heeron.Hamid Khoja, the biotechnology company's chief scientific officer said, \"unlike traditional treatments, fibroblasts may offer a potential solution aligned with the host biological processes to help regulate immune activity within the spleen, opening new possibilities for managing conditions that involve immune system overload and splenomegaly.\"Price: 2.41, Change: -0.09, Percent Change: -3.75","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}